Skip to main content
Erschienen in: CNS Drugs 8/2007

01.08.2007 | Review Article

CNS Aspergillosis

Recognition, Diagnosis and Management

verfasst von: Prof. Markus Ruhnke, Grzegorz Kofla, Kirsten Otto, Stefan Schwartz

Erschienen in: CNS Drugs | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Early diagnosis of CNS aspergillosis requires a high degree of clinical suspicion, because there are no typical clinical symptoms or CSF findings. Clinical features are usually dramatic and tend to progress rapidly. Changes in mental status, hemiparesis and seizures are most common, but other nonspecific neurological features may occur and should always be an indication for neuroradiological examination in high risk patients, in order to allow early initiation of antifungal therapy. Low density lesions with little or no mass effect and minimal or no contrast enhancement on CT scans that are usually more numerous on MRI and show intermediate signal intensity within high-signal areas on T2-weighted images, may suggest CNS aspergillosis. Cerebral lesions in CNS aspergillosis are often located, not only in the cerebral hemispheres but also in the basal ganglia, thalami, corpus callosum and perforator artery territories. There is frequently a lack of contrast enhancement or perifocal oedema, due to the immunosuppressed status of the patient. A definite diagnosis requires brain tissue for histopathological analysis. However, neurosurgery is often not feasible, so that any of the neuroradiological findings mentioned above should raise the suspicion of CNS aspergillosis in immunocompromised patients and lead to early initiation of antifungal therapy.
In the past, amphotericin B-based therapy was the treatment of choice for CNS aspergillosis, but this treatment produced negligible effects. Recently, voriconazole has been reported to be more effective than amphotericin B in the treatment of invasive aspergillosis. Response rates of about 35% have been achieved with voriconazole in patients with CNS aspergillosis. Combination therapy with antifungal agents, such as voriconazole plus caspofungin or liposomal amphotericin B, is being investigated in vitro and in animal models and optimistic results have been observed. A combined medical and neurosurgical treatment should be considered in all patients with this disease.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement
 
Literatur
1.
Zurück zum Zitat Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013–25PubMedCrossRef Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013–25PubMedCrossRef
2.
Zurück zum Zitat Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33: 116–24PubMedCrossRef Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33: 116–24PubMedCrossRef
3.
Zurück zum Zitat Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood 2005 Oct 15; 106(8): 2641–5PubMedCrossRef Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood 2005 Oct 15; 106(8): 2641–5PubMedCrossRef
4.
Zurück zum Zitat Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 Feb 1; 32(3): 358–66PubMedCrossRef Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 Feb 1; 32(3): 358–66PubMedCrossRef
5.
Zurück zum Zitat Maschke M, Dietrich U, Prumbaum M, et al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1167–76PubMedCrossRef Maschke M, Dietrich U, Prumbaum M, et al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1167–76PubMedCrossRef
6.
Zurück zum Zitat Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15PubMedCrossRef Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15PubMedCrossRef
7.
Zurück zum Zitat Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875–94PubMedCrossRef Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875–94PubMedCrossRef
8.
Zurück zum Zitat Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000; 30: 696–709PubMedCrossRef Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000; 30: 696–709PubMedCrossRef
9.
Zurück zum Zitat Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 2000 Jul; 79(4): 250–60 Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 2000 Jul; 79(4): 250–60
10.
Zurück zum Zitat Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 1985; 18: 574–82PubMedCrossRef Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 1985; 18: 574–82PubMedCrossRef
11.
Zurück zum Zitat Donhuijsen K, Pfaffenbach B, Samandari S, et al. Autopsy results of deep-seated mycosis occurring with haematologic neoplasia (1053 patients). Mykosen 1991; 34 Suppl.: 25–7 Donhuijsen K, Pfaffenbach B, Samandari S, et al. Autopsy results of deep-seated mycosis occurring with haematologic neoplasia (1053 patients). Mykosen 1991; 34 Suppl.: 25–7
12.
Zurück zum Zitat Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109PubMedCrossRef Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109PubMedCrossRef
13.
Zurück zum Zitat Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732–8PubMed Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732–8PubMed
14.
Zurück zum Zitat Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003 Nov; 53(11): 744–50PubMedCrossRef Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003 Nov; 53(11): 744–50PubMedCrossRef
15.
Zurück zum Zitat Hori A, Kami M, Kishi Y, et al. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002 Mar; 50(3): 175–82PubMedCrossRef Hori A, Kami M, Kishi Y, et al. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002 Mar; 50(3): 175–82PubMedCrossRef
16.
Zurück zum Zitat Pagano L, Ricci P, Montillo M, et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell’Adulto Infection Program. Clin Infect Dis 1996; 23: 628–30 Pagano L, Ricci P, Montillo M, et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell’Adulto Infection Program. Clin Infect Dis 1996; 23: 628–30
17.
Zurück zum Zitat Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191–6PubMedCrossRef Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191–6PubMedCrossRef
18.
Zurück zum Zitat Hagensee ME, Bauwens JE, Kjos B, et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984–1992. Clin Infect Dis 1994; 19: 402–8PubMedCrossRef Hagensee ME, Bauwens JE, Kjos B, et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984–1992. Clin Infect Dis 1994; 19: 402–8PubMedCrossRef
19.
Zurück zum Zitat Wald A, Leisenring W, van-Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–66PubMedCrossRef Wald A, Leisenring W, van-Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–66PubMedCrossRef
20.
Zurück zum Zitat Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–30PubMedCrossRef Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–30PubMedCrossRef
21.
Zurück zum Zitat Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985; 35: 1654–7PubMedCrossRef Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985; 35: 1654–7PubMedCrossRef
22.
Zurück zum Zitat Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 Jan; 18(1): 44–69PubMedCrossRef Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 Jan; 18(1): 44–69PubMedCrossRef
23.
Zurück zum Zitat Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003 Mar; 3(3): 156–61PubMedCrossRef Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003 Mar; 3(3): 156–61PubMedCrossRef
24.
Zurück zum Zitat Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003 Jan 1; 36(1): 46–52PubMedCrossRef Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003 Jan 1; 36(1): 46–52PubMedCrossRef
25.
Zurück zum Zitat Mylonakis E, Paliou M, Sax PE, et al. Central nervous system aspergillosis in patients with human immunodeficiency virus infection: report of 6 cases and review. Medicine (Baltimore) 2000 Jul; 79(4): 269–80CrossRef Mylonakis E, Paliou M, Sax PE, et al. Central nervous system aspergillosis in patients with human immunodeficiency virus infection: report of 6 cases and review. Medicine (Baltimore) 2000 Jul; 79(4): 269–80CrossRef
26.
Zurück zum Zitat Guermazi A, Gluckman E, Tabti B, et al. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003; 13: 377–88PubMedCrossRef Guermazi A, Gluckman E, Tabti B, et al. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003; 13: 377–88PubMedCrossRef
27.
Zurück zum Zitat Torre-Cisneros J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1993; 56: 188–93PubMedCrossRef Torre-Cisneros J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1993; 56: 188–93PubMedCrossRef
28.
Zurück zum Zitat Shuper A, Levitsky KI, Cornblath DR. Early invasive CNS aspergillosis: an easily missed diagnosis. Neuroradiology 1991; 33: 183–5PubMedCrossRef Shuper A, Levitsky KI, Cornblath DR. Early invasive CNS aspergillosis: an easily missed diagnosis. Neuroradiology 1991; 33: 183–5PubMedCrossRef
29.
Zurück zum Zitat Coley SC, Jager HR, Szydlo RM, et al. CT and MRI manifestations of central nervous system infection following allogeneic bone marrow transplantation. Clin Radiol 1999; 54: 390–7PubMedCrossRef Coley SC, Jager HR, Szydlo RM, et al. CT and MRI manifestations of central nervous system infection following allogeneic bone marrow transplantation. Clin Radiol 1999; 54: 390–7PubMedCrossRef
30.
Zurück zum Zitat Okafuji T, Yabuuchi H, Nagatoshi Y, et al. CT and MR findings of brain aspergillosis. Comput Med Imaging Graph 2003; 27: 489–92PubMedCrossRef Okafuji T, Yabuuchi H, Nagatoshi Y, et al. CT and MR findings of brain aspergillosis. Comput Med Imaging Graph 2003; 27: 489–92PubMedCrossRef
31.
Zurück zum Zitat Boes B, Bashir R, Boes C, et al. Central nervous system aspergillosis: analysis of 26 patients. J Neuroimaging 1994; 4: 123–9PubMed Boes B, Bashir R, Boes C, et al. Central nervous system aspergillosis: analysis of 26 patients. J Neuroimaging 1994; 4: 123–9PubMed
32.
Zurück zum Zitat Murthy JM, Sundaram C, Prasad VS, et al. Aspergillosis of central nervous system: a study of 21 patients seen in a university hospital in south India. J Assoc Physicians India 2000; 48: 677–81PubMed Murthy JM, Sundaram C, Prasad VS, et al. Aspergillosis of central nervous system: a study of 21 patients seen in a university hospital in south India. J Assoc Physicians India 2000; 48: 677–81PubMed
33.
Zurück zum Zitat Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery 2004; 55: 602–11, discussion 611-3PubMedCrossRef Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery 2004; 55: 602–11, discussion 611-3PubMedCrossRef
34.
Zurück zum Zitat Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994 Sep; 140 (Pt 9): 2475–9PubMedCrossRef Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994 Sep; 140 (Pt 9): 2475–9PubMedCrossRef
35.
Zurück zum Zitat Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079–86PubMed Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079–86PubMed
36.
Zurück zum Zitat Balloy V, Huerre M, Latge JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005 Jan; 73(1): 494–503PubMedCrossRef Balloy V, Huerre M, Latge JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005 Jan; 73(1): 494–503PubMedCrossRef
37.
Zurück zum Zitat Verweij PE, Brinkman K, Kremer HPH, et al. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186–9PubMed Verweij PE, Brinkman K, Kremer HPH, et al. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186–9PubMed
38.
Zurück zum Zitat Kami M, Ogawa S, Kanda Y, et al. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999; 106: 536–7PubMedCrossRef Kami M, Ogawa S, Kanda Y, et al. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999; 106: 536–7PubMedCrossRef
39.
Zurück zum Zitat Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496–9PubMedCrossRef Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496–9PubMedCrossRef
40.
Zurück zum Zitat Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–57PubMedCrossRef Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–57PubMedCrossRef
41.
Zurück zum Zitat Cox J, Murtagh FR, Wilfong A, et al. Cerebral aspergillosis: MR imaging and histopathologic correlation. Am J Neuroradiol 1992; 13: 1489–92PubMed Cox J, Murtagh FR, Wilfong A, et al. Cerebral aspergillosis: MR imaging and histopathologic correlation. Am J Neuroradiol 1992; 13: 1489–92PubMed
42.
Zurück zum Zitat Yuh WT, Nguyen HD, Gao F, et al. Brain parenchymal infection in bone marrow transplantation patients: CT and MR findings. Am J Roentgenol 1994 Feb; 162(2): 425–30 Yuh WT, Nguyen HD, Gao F, et al. Brain parenchymal infection in bone marrow transplantation patients: CT and MR findings. Am J Roentgenol 1994 Feb; 162(2): 425–30
43.
Zurück zum Zitat Miaux Y, Ribaud P, Williams M, et al. MR of cerebral aspergillosis in patients who have had bone marrow transplantation. Am J Neuroradiol 1995 Mar; 16(3): 555–62PubMed Miaux Y, Ribaud P, Williams M, et al. MR of cerebral aspergillosis in patients who have had bone marrow transplantation. Am J Neuroradiol 1995 Mar; 16(3): 555–62PubMed
44.
Zurück zum Zitat DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain: distribution and imaging characteristics. Am J Neuroradiol 1999 Oct; 20(9): 1597–604PubMed DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain: distribution and imaging characteristics. Am J Neuroradiol 1999 Oct; 20(9): 1597–604PubMed
45.
Zurück zum Zitat Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. Am J Roentgenol 1994; 162: 155–9 Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. Am J Roentgenol 1994; 162: 155–9
46.
Zurück zum Zitat Dietrich U, Hettmann M, Maschke M, et al. Cerebral aspergillosis: comparison of radiological and neuropathologic findings in patients with bone marrow transplantation. Eur Radiol 2001; 11: 1242–9PubMedCrossRef Dietrich U, Hettmann M, Maschke M, et al. Cerebral aspergillosis: comparison of radiological and neuropathologic findings in patients with bone marrow transplantation. Eur Radiol 2001; 11: 1242–9PubMedCrossRef
47.
Zurück zum Zitat Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006; 61(5): 393–401PubMedCrossRef Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006; 61(5): 393–401PubMedCrossRef
48.
Zurück zum Zitat Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710–8CrossRef Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710–8CrossRef
49.
Zurück zum Zitat van-Burik JA, Hackman RC, Nadeem SQ, et al. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 1997; 24: 1154–60PubMedCrossRef van-Burik JA, Hackman RC, Nadeem SQ, et al. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 1997; 24: 1154–60PubMedCrossRef
50.
Zurück zum Zitat Goodman JS, Kaufman L, Koenig MG. Diagnosis of cryptococcal meningitis. N Engl J Med 1971; 285: 434–6PubMedCrossRef Goodman JS, Kaufman L, Koenig MG. Diagnosis of cryptococcal meningitis. N Engl J Med 1971; 285: 434–6PubMedCrossRef
51.
Zurück zum Zitat Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611–6PubMedCrossRef Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611–6PubMedCrossRef
52.
Zurück zum Zitat Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000 Jul; 37(3): 169–79PubMedCrossRef Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000 Jul; 37(3): 169–79PubMedCrossRef
53.
Zurück zum Zitat Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991 Mar–Apr; 13 (2): 345]. Rev Infect Dis 1990; 12: 1147–201PubMedCrossRef Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991 Mar–Apr; 13 (2): 345]. Rev Infect Dis 1990; 12: 1147–201PubMedCrossRef
54.
Zurück zum Zitat Patterson TF, George D, Ingersoll R, et al. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991; 35: 1985–8PubMedCrossRef Patterson TF, George D, Ingersoll R, et al. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991; 35: 1985–8PubMedCrossRef
55.
Zurück zum Zitat Andriole VT, Miniter P, George D, et al. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992; 14Suppl. 1: S134–8PubMedCrossRef Andriole VT, Miniter P, George D, et al. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992; 14Suppl. 1: S134–8PubMedCrossRef
56.
Zurück zum Zitat Roberts J, Schock K, Marino S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echino-candin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381–8PubMedCrossRef Roberts J, Schock K, Marino S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echino-candin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381–8PubMedCrossRef
57.
Zurück zum Zitat Troke PF, Andrews RJ, Marriott MS, et al. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother 1987 May; 19(5): 663–70PubMedCrossRef Troke PF, Andrews RJ, Marriott MS, et al. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother 1987 May; 19(5): 663–70PubMedCrossRef
58.
Zurück zum Zitat Chiller TM, Luque JC, Sobel RA, et al. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002; 186: 574–7PubMedCrossRef Chiller TM, Luque JC, Sobel RA, et al. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002; 186: 574–7PubMedCrossRef
59.
Zurück zum Zitat Chiller TM, Sobel RA, Luque JC, et al. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813–5PubMedCrossRef Chiller TM, Sobel RA, Luque JC, et al. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813–5PubMedCrossRef
60.
Zurück zum Zitat Clemons KV, Espiritu M, Parmar R, et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–75PubMedCrossRef Clemons KV, Espiritu M, Parmar R, et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–75PubMedCrossRef
61.
Zurück zum Zitat Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–8PubMedCrossRef Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–8PubMedCrossRef
62.
Zurück zum Zitat Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37Suppl. 3: S188–224PubMedCrossRef Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37Suppl. 3: S188–224PubMedCrossRef
63.
Zurück zum Zitat Boon AP, Adams DH, Buckels J, et al. Cerebral aspergillosis in liver transplantation. J Clin Pathol 1990; 43: 114–8PubMedCrossRef Boon AP, Adams DH, Buckels J, et al. Cerebral aspergillosis in liver transplantation. J Clin Pathol 1990; 43: 114–8PubMedCrossRef
64.
Zurück zum Zitat Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–24PubMedCrossRef Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–24PubMedCrossRef
65.
Zurück zum Zitat Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 Mar 1; 32(5): 686–93PubMedCrossRef Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 Mar 1; 32(5): 686–93PubMedCrossRef
66.
Zurück zum Zitat Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001 Nov; 111(7): 528–34PubMedCrossRef Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001 Nov; 111(7): 528–34PubMedCrossRef
67.
Zurück zum Zitat Ehrmann S, Bastides F, Gissot V, et al. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Med 2005 May; 31(5): 738–42PubMedCrossRef Ehrmann S, Bastides F, Gissot V, et al. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Med 2005 May; 31(5): 738–42PubMedCrossRef
68.
Zurück zum Zitat Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32: E137–9PubMedCrossRef Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32: E137–9PubMedCrossRef
69.
Zurück zum Zitat Darras-Joly C, Veber B, Bedos JP, et al. Nosocomial cerebral aspergillosis: a report of 3 cases. Scand J Infect Dis 1996; 28: 317–9PubMedCrossRef Darras-Joly C, Veber B, Bedos JP, et al. Nosocomial cerebral aspergillosis: a report of 3 cases. Scand J Infect Dis 1996; 28: 317–9PubMedCrossRef
70.
Zurück zum Zitat Kerkmann ML, Blaschke-Hellmessen R, Mikulin HD. Successful treatment of cerebral aspergillosis by stereotactic operation and antifungal therapy. Mycoses 1994; 37: 123–6PubMedCrossRef Kerkmann ML, Blaschke-Hellmessen R, Mikulin HD. Successful treatment of cerebral aspergillosis by stereotactic operation and antifungal therapy. Mycoses 1994; 37: 123–6PubMedCrossRef
71.
Zurück zum Zitat Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med 1999 Oct; 38(10): 829–32PubMedCrossRef Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med 1999 Oct; 38(10): 829–32PubMedCrossRef
72.
Zurück zum Zitat Sanchez C, Mauri E, Dalmau D, et al. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 1995; 21: 1485–7PubMedCrossRef Sanchez C, Mauri E, Dalmau D, et al. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 1995; 21: 1485–7PubMedCrossRef
73.
Zurück zum Zitat Coleman JM, Hogg GG, Rosenfeld JV, et al. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery: case report and review of the literature. Neurosurgery 1995; 36: 858–63PubMedCrossRef Coleman JM, Hogg GG, Rosenfeld JV, et al. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery: case report and review of the literature. Neurosurgery 1995; 36: 858–63PubMedCrossRef
74.
Zurück zum Zitat Camarata PJ, Dunn DL, Farney AC, et al. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of aspergillus brain abscess: case report and review of the literature. Neurosurgery 1992; 31: 575–9PubMedCrossRef Camarata PJ, Dunn DL, Farney AC, et al. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of aspergillus brain abscess: case report and review of the literature. Neurosurgery 1992; 31: 575–9PubMedCrossRef
75.
Zurück zum Zitat Goodman ML, Coffey RJ. Stereotactic drainage of aspergillus brain abscess with long-term survival: case report and review. Neurosurgery 1989; 24: 94–6 Goodman ML, Coffey RJ. Stereotactic drainage of aspergillus brain abscess with long-term survival: case report and review. Neurosurgery 1989; 24: 94–6
76.
Zurück zum Zitat Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–44PubMedCrossRef Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–44PubMedCrossRef
77.
Zurück zum Zitat Walsh TJ, Hiemenz JW, Scibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–96PubMedCrossRef Walsh TJ, Hiemenz JW, Scibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–96PubMedCrossRef
78.
Zurück zum Zitat Kaiser L, Huguenin T, Lew PD, et al. Invasive aspergillosis: clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188–94CrossRef Kaiser L, Huguenin T, Lew PD, et al. Invasive aspergillosis: clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188–94CrossRef
79.
Zurück zum Zitat de Lastours V, Lefort A, Zappa M, et al. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003; 22: 297–9PubMed de Lastours V, Lefort A, Zappa M, et al. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003; 22: 297–9PubMed
80.
Zurück zum Zitat Tattevin P, Bruneel F, Lellouche F, et al. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect 2004 Oct; 10(10): 928–31PubMedCrossRef Tattevin P, Bruneel F, Lellouche F, et al. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect 2004 Oct; 10(10): 928–31PubMedCrossRef
81.
Zurück zum Zitat Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 Oct; 56(4): 745–55PubMedCrossRef Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 Oct; 56(4): 745–55PubMedCrossRef
82.
Zurück zum Zitat Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2: 140–4PubMedCrossRef Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2: 140–4PubMedCrossRef
83.
Zurück zum Zitat Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343–501PubMedCrossRef Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343–501PubMedCrossRef
84.
Zurück zum Zitat Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89PubMedCrossRef Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89PubMedCrossRef
85.
Zurück zum Zitat Heykants J, Van-Peer A, Van-de-Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32Suppl. 1: 67–87PubMed Heykants J, Van-Peer A, Van-de-Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32Suppl. 1: 67–87PubMed
86.
Zurück zum Zitat Collette N, Van-der-Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33: 362–8PubMedCrossRef Collette N, Van-der-Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33: 362–8PubMedCrossRef
87.
Zurück zum Zitat Collette N, Van-der-Auwera P, Meunier F, et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991 Apr; 27(4): 535–48PubMedCrossRef Collette N, Van-der-Auwera P, Meunier F, et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991 Apr; 27(4): 535–48PubMedCrossRef
89.
Zurück zum Zitat Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003 Feb; 4(2): 179–85PubMed Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003 Feb; 4(2): 179–85PubMed
90.
Zurück zum Zitat Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 Jul; 182(1): 274–82PubMedCrossRef Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 Jul; 182(1): 274–82PubMedCrossRef
91.
Zurück zum Zitat Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996 May; 22Suppl. 2: S133–44PubMedCrossRef Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996 May; 22Suppl. 2: S133–44PubMedCrossRef
92.
Zurück zum Zitat Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 Sep 1; 37(5): 728–32PubMedCrossRef Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 Sep 1; 37(5): 728–32PubMedCrossRef
93.
Zurück zum Zitat Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005; 6: 1215–9PubMedCrossRef Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005; 6: 1215–9PubMedCrossRef
96.
Zurück zum Zitat Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004 Aug; 2(4): 499–508PubMedCrossRef Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004 Aug; 2(4): 499–508PubMedCrossRef
97.
Zurück zum Zitat Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15PubMedCrossRef Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15PubMedCrossRef
98.
Zurück zum Zitat Marbello L, Nosari A, Carrafiello G, et al. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient [letter]. Haematologica 2003; 88(3): ECR05PubMed Marbello L, Nosari A, Carrafiello G, et al. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient [letter]. Haematologica 2003; 88(3): ECR05PubMed
99.
Zurück zum Zitat Damaj G, Ivanov V, Le Brigand B, et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol 2004; 83: 390–3PubMedCrossRef Damaj G, Ivanov V, Le Brigand B, et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol 2004; 83: 390–3PubMedCrossRef
100.
Zurück zum Zitat Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 Sep 15; 39(6): 797–802PubMedCrossRef Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 Sep 15; 39(6): 797–802PubMedCrossRef
101.
Zurück zum Zitat Elgamal EA, Murshid WR. Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literature. Br J Neurosurg 2000 Apr; 14(2): 137–41PubMedCrossRef Elgamal EA, Murshid WR. Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literature. Br J Neurosurg 2000 Apr; 14(2): 137–41PubMedCrossRef
Metadaten
Titel
CNS Aspergillosis
Recognition, Diagnosis and Management
verfasst von
Prof. Markus Ruhnke
Grzegorz Kofla
Kirsten Otto
Stefan Schwartz
Publikationsdatum
01.08.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 8/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721080-00004

Weitere Artikel der Ausgabe 8/2007

CNS Drugs 8/2007 Zur Ausgabe

Therapy in Practice

Depression in Nursing Homes

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.